Reta Melese Abate, Said Halima M, Maningi Nontuthuko Excellent, Wubetu Gizachew Yismaw, Agonafir Mulualem, Fourie P Bernard
Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Department of Medical Laboratory Science, College of Health Sciences, Woldia University, Woldia, Ethiopia.
New Microbes New Infect. 2024 Mar 8;59:101235. doi: 10.1016/j.nmni.2024.101235. eCollection 2024 Jun.
The genetic diversity of complex (MTBC) strains was characterized among isolates from individuals with pulmonary tuberculosis (PTB) symptoms attended holy water sites (HWSs) in the Amhara region, Ethiopia.
A cross-sectional study was done from June 2019 to March 2020 to describe the genetic diversity and drug-resistance profiles of MTBC isolates. Sputum specimens were collected and cultured in the Löwenstein-Jensen culture medium. Line Probe Assay, MTBDR VER 2.0, and MTBDR VER 2.0 were used to detect first-and second-line anti-TB drug-resistance patterns. A spoligotyping technique was utilized to characterize the genetic diversity. Statistical analysis was performed using STATA 15.
Of 560 PTB-symptomatic participants, 122 (21.8%) were culture-positive cases. Spoligotyping of 116 isolates revealed diverse MTBC sublineages, with four major lineages: Euro-American (EA) (Lineage 4), East-African-Indian (EAI) (Lineage 3), Ethiopian (ETH) (Lineage 7), East Asian (EA) (Lineage 2). The majority (96.6%) of the isolates were EA (lineage 4) and EAI, with proportions of 54.3% and 42.2%, respectively. A total of 31 spoligotype patterns were identified, 26 of which were documented in the SITVIT2 database. Of these, there were 15 unique spoligotypes, while eleven were grouped with 2-17 isolates. SIT149/T3-ETH (n = 17), SIT26/CAS1-DELHI (n = 16), SIT25/CAS1-DELHI (n = 12), and SIT52/T2 (n = 11) spoligotypes were predominant. A rare spoligotype pattern: SIT41/Turkey and SIT1/Beijing, has also been identified in North Shewa. The overall clustering rate of sub-lineages with known SIT was 76.4%.Of the 122 culture-positive isolates tested, 16.4% were resistant to rifampicin (RIF) and/or isoniazid (INH). Multidrug-resistant TB (MDR-TB) was detected in 12.3% of isolates, five of which were fluoroquinolones (FLQs) resistant. SIT149/T3-ETH and SIT21/CAS1-KILI sublineages showed a higher proportion of drug resistance.
Diverse MTBC spoligotypes were identified, with the T and CAS families and EA (lineage 4) predominating. A high prevalence of drug-resistant TB, with SIT149/T3-ETH and CAS1-KILI sublineages comprising a greater share, was observed. A study with large sample size and a sequencing method with stronger discriminatory power is warranted to understand better the genetic diversity of circulating MTBC in this cohort of study, which would help to adopt targeted interventions.
在埃塞俄比亚阿姆哈拉地区前往圣水地点(HWSs)就诊的有肺结核(PTB)症状个体的分离株中,对复合分枝杆菌(MTBC)菌株的遗传多样性进行了表征。
于2019年6月至2020年3月进行了一项横断面研究,以描述MTBC分离株的遗传多样性和耐药谱。收集痰标本并在罗 - 琴培养基中培养。使用线性探针测定法、MTBDR VER 2.0和MTBDR VER 2.0检测一线和二线抗结核药物耐药模式。采用间隔寡核苷酸分型技术来表征遗传多样性。使用STATA 15进行统计分析。
在560名有PTB症状的参与者中,122例(21.8%)为培养阳性病例。对116株分离株进行的间隔寡核苷酸分型揭示了不同的MTBC亚谱系,有四个主要谱系:欧美(EA)(谱系4)、东非 - 印度(EAI)(谱系3)、埃塞俄比亚(ETH)(谱系7)、东亚(EA)(谱系2)。大多数(96.6%)分离株为EA(谱系4)和EAI,比例分别为54.3%和42.2%。共鉴定出31种间隔寡核苷酸分型模式,其中26种记录在SITVIT2数据库中。其中,有15种独特的间隔寡核苷酸分型,而11种与2 - 17株分离株归为一组。SIT149/T3 - ETH(n = 17)、SIT26/CAS1 - DELHI(n = 16)、SIT25/CAS1 - DELHI(n = 12)和SIT52/T2(n = 11)间隔寡核苷酸分型占主导地位。在北谢瓦还鉴定出一种罕见的间隔寡核苷酸分型模式:SIT41/土耳其和SIT1/北京。已知SIT的亚谱系的总体聚类率为76.4%。在122株检测的培养阳性分离株中,16.4%对利福平(RIF)和/或异烟肼(INH)耐药。在12.3%的分离株中检测到耐多药结核病(MDR - TB),其中5株对氟喹诺酮类(FLQs)耐药。SIT149/T3 - ETH和SIT21/CAS1 - KILI亚谱系显示出较高比例的耐药性。
鉴定出了不同的MTBC间隔寡核苷酸分型,T和CAS家族以及EA(谱系4)占主导。观察到耐多药结核病的高患病率,其中SIT149/T3 - ETH和CAS1 - KILI亚谱系占比更大。有必要进行一项大样本量的研究,并采用具有更强鉴别力的测序方法,以更好地了解该研究队列中循环MTBC的遗传多样性,这将有助于采取有针对性的干预措施。